DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02750501 (ClinicalTrials.gov)	July 20, 2016	20/4/2016	Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study	Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study in Patients With Cystic Fibrosis Receiving Enteral Feeding	Cystic Fibrosis	Device: RELiZORB (immobilized lipase) cartridge;Other: Impact Peptide 1.5	Alcresta Therapeutics, Inc.	Cystic Fibrosis Foundation	Completed	4 Years	N/A	All	49	N/A	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

July 20, 2016

20/4/2016

Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study

Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study in Patients With Cystic Fibrosis Receiving Enteral Feeding

Cystic Fibrosis

Device: RELiZORB (immobilized lipase) cartridge;Other: Impact Peptide 1.5

Alcresta Therapeutics, Inc.

Cystic Fibrosis Foundation

Completed

4 Years

N/A

All

N/A

United States